128.67 0.71 (0.55%) | 02-19 13:57 | |||||||||||||
|
|
Short term | ![]() ![]() ![]() |
|||
Mid term | ![]() |
|||
Targets | 6-month : | 150.38 ![]() |
1-year : | 175.64 ![]() |
Resists | First : | 128.75 ![]() |
Second : | 150.38 ![]() |
Pivot price | 127.43 ![]() |
|||
Supports | First : | 127.05 ![]() |
Second : | 126 |
MAs | MA(5) : | 128.1 ![]() |
MA(20) : | 127.36 ![]() |
MA(100) : | 93.7 ![]() |
MA(250) : | 80.38 ![]() |
|
MACD | MACD : | 5.4 ![]() |
Signal : | 6.8 ![]() |
%K %D | K(14,3) : | 85 ![]() |
D(3) : | 85.4 ![]() |
RSI | RSI(14): 84.4 ![]() |
|||
52-week | High : | 128.75 | Low : | 62.77 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ ITCI ] has closed It is unclear right now based on current values. 87.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 11 bars. This is a sign that the market may be about to initiate a new trend.
If tomorrow: | Open lower | Open higher |
High: | 128.27 - 128.78 | 128.78 - 129.22 |
Low: | 126.47 - 127.11 | 127.11 - 127.66 |
Close: | 126.87 - 127.9 | 127.9 - 128.79 |
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in developing lumateperone, which is in Phase III clinical trial for the treatment of bipolar depression, as well as to treat autism spectrum disorder; and in additional neuropsychiatric indications, such as sleep disorders associated with neuropsychiatric and neurological disorders. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease and heart failure; ITI-1284-ODT-SL for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.
Wed, 19 Feb 2025
TimesSquare Capital Management LLC Buys 402,186 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Wed, 19 Feb 2025
Quantum Private Wealth LLC Sells 8,519 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Mon, 17 Feb 2025
Intra-Cellular Therapies Stock Soars to All-Time High of $128.01 - MSN
Mon, 13 Jan 2025
J&J to buy neurological drugmaker Intra-Cellular for $14.6 billion - CNBC
Mon, 13 Jan 2025
Intra-Cellular Therapies Stock Pops as Johnson & Johnson Buys Firm for $14.6B - Investopedia
Mon, 13 Jan 2025
ITCI Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Intra-Cellular Therapies, Inc. Is Fair to Shareholders - Business Wire
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
Shares Out | 106 (M) |
Shares Float | 104 (M) |
Held by Insiders | 3.2 (%) |
Held by Institutions | 96.9 (%) |
Shares Short | 1,600 (K) |
Shares Short P.Month | 1,980 (K) |
EPS | -0.88 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 10.8 |
Profit Margin | -14.1 % |
Operating Margin | -22.2 % |
Return on Assets (ttm) | -7.5 % |
Return on Equity (ttm) | -9.9 % |
Qtrly Rev. Growth | 39 % |
Gross Profit (p.s.) | 3.29 |
Sales Per Share | 5.77 |
EBITDA (p.s.) | -1.14 |
Qtrly Earnings Growth | 0 % |
Operating Cash Flow | -62 (M) |
Levered Free Cash Flow | -7 (M) |
PE Ratio | -147.96 |
PEG Ratio | 0 |
Price to Book value | 11.91 |
Price to Sales | 22.28 |
Price to Cash Flow | -220.01 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |